source
- Roche talks up Phase 3 success rate as it unveils pipeline cutsWhere other European pharmas — notably Novartis, Novo and AstraZeneca — have suffered huge late-stage clinical failures this summer, Roche is feeling rather smug. CEO Thomas Schinecker said ...Endpoints · 1h ago↗ source
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cureGSK and Ionis announced that the U.S. Food and Drug Administration has approved their hepatitis B drug bepirovirsen, now marketed as Hibsago. The therapy is intended for chronic hepatitis B patien…